OptimizeRx Corp — Director's Dealing 2024

Feb 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2023-12-19

Reporting Person: Odence-Ford Marion (General Counsel and CCO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-19	Stock Option	$12.73	A	11783	Acquired	2026-12-19	Common Stock (11783)	Direct
2023-12-19	Restricted Stock Units	$	A	11783	Acquired	2026-12-19	Common Stock (11783)	Direct

Footnotes

F1: The stock options vest in three equal annual installments beginning October 19, 2024, the first anniversary of the grant date.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The restricted stock units vest in three equal annual installments beginning October 19, 2024, the first anniversary of the grant date.